Drug-disease and drug-drug interactions: Systematic examination of recommendations in 12 UK national clinical guidelines

BMJ (Online)

Volumn 350, Issue , 2015, Pages 1-8

  Dumbreck, Siobhan ^a   Flynn, Angela ^a   Nairn, Moray ^b   Wilson, Martin ^c   Treweek, Shaun ^d   Mercer, Stewart W ^e   Alderson, Phil ^f   Thompson, Alex ^g   Payne, Katherine ^g   Guthrie, Bruce ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b HEALTHCARE IMPROVEMENT SCOTLAND   (United Kingdom)

^c RAIGMORE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; DOMPERIDONE; ERYTHROMYCIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; LITHIUM CARBONATE; METFORMIN; METOCLOPRAMIDE; OMEGA 3 FATTY ACID; PHOSPHODIESTERASE V INHIBITOR; POTASSIUM SPARING DIURETIC AGENT; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; SPIRONOLACTONE; SULFONYLUREA; THEOPHYLLINE; UNINDEXED DRUG; VERAPAMIL; ANTIDIABETIC AGENT;

ANGINA PECTORIS; ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DEPRESSION; DRUG CHOICE; DRUG DISEASE INTERACTION; DRUG DRUG INTERACTION; DRUG INTERACTION; HEART FAILURE; HYPERTENSION; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM; CONTRAINDICATIONS; DEPRESSIVE DISORDER; DIABETES MELLITUS, TYPE 2; GREAT BRITAIN; HUMAN; RENAL INSUFFICIENCY, CHRONIC;

ANTIDEPRESSIVE AGENTS; COMORBIDITY; DEPRESSIVE DISORDER; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; GREAT BRITAIN; HEART FAILURE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84943014080     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h949     Document Type: Article

References (42)

1. Barnett K, Mercer S, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for healthcare, research, and medical education: a cross-sectional study. Lancet 2012;380:37-43.
2. Guthrie B, Payne K, Alderson P, McMurdo M, Mercer S. Adapting clinical guidelines to take account of multimorbidity. BMJ 2012;345:e6341.
3. Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ 2011;342:d3514.
4. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Safety 2010;19:901-10.
5. Boyd C, Darer J, Boult C, Fried L, Boult L, Wu A. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases implications for pay for performance. JAMA 2005;294:716-24.
6. House of Commons Health Committee. Managing the care of people with long-term conditions. Stationery Office, July 2014:222 (HC401). www.publications.parliament.uk/pa/cm201415/cmselect/cmhealth/401/401.pdf
7. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley T, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-9.
8. Calderon-Larranaga A, Poblador-Plou B, Gonzalez-Rubio F, Gimeno-Feliu LA, Abad-Diez JM, Prados-Torres A. Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well? Br J Gen Prac 2012;62:e821-6.
9. Marengoni A, Pasina L, Concoreggi C, Martini G, Brognoli F, Nobili A, et al. Understanding adverse drug reactions in older adults through drug-drug interactions. Eur J Intern Med 2014;25:843-6.
10. Schedlbauer A, Prasad V, Mulvaney C, Phansalkar S, Stanton W, Bates DW, et al. What evidence supports the use of computerized alerts and prompts to improve clinicians' prescribing behavior? J Am Med Inform Assoc 2009;16:531-8.
11. Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008. BMC Clin Pharmacol 2010;10:16.
12. Zhang M, Holman CD, Price SD, Sanfilippo FM, Preen DB, Bulsara MK. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ 2009;338:a2752.
13. American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians. J Am Geriatr Soc 2012;60:e1-25.
14. Chronic heart failure. Management of chronic heart failure in adults in primary and secondary care (NICE Clinical Guideline 108). National Institute for Health and Care Excellence, 2010.
15. The management of type 2 diabetes (NICE Clinical Guideline 87). National Institute for Health and Care Excellence, 2010.
16. The treatment and management of depression in adults (NICE Clinical Guideline 90). National Institute for Health and Care Excellence, 2009.
17. The management of atrial fibrillation (NICE Clinical Guideline 36). National Institute for Health and Care Excellence, 2006.
18. The care and management of osteoarthritis in adults (NICE Clinical Guideline 59). National Institute for Health and Care Excellence, 2008.
19. Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update) (NICE Clinical Guideline 101). National Institute for Health and Care Excellence, 2010.
20. Clinical management of primary hypertension in adults (NICE Clinical Guideline 127). National Institute for Health and Care Excellence, 2011.
21. Secondary prevention in primary and secondary care for patients following a myocardial infarction (NICE Clinical Guideline 48). National Institute for Health and Care Excellence, 2007.
22. Supporting people with dementia and their carers in health and social care (NICE Clinical Guideline 42). National Institute for Health and Care Excellence, 2006 (amended 2011).
23. The management of rheumatoid arthritis in adults (NICE Clinical Guideline 79). National Institute for Health and Care Excellence, 2009.
24. Early identification and management of chronic kidney disease in adults in primary and secondary care (NICE Clinical Guideline 73). National Institute for Health and Care Excellence, 2008.
25. The pharmacological management of neuropathic pain in adults in non-specialist settings (NICE Clinical Guideline 96). National Institute for Health and Care Excellence, 2010.
26. British National Formulary. 66th ed. British Medical Association and Royal Pharmaceutical Society of Great Britain, 2013.
27. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300:2514-26.
28. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. Age Ageing 2013;42:62-9.
29. Lorgunpai SJ, Grammas M, Lee DS, McAvay G, Charpentier P, Tinetti ME. Potential therapeutic competition in community-living older adults in the US: use of medications that may adversely affect a coexisting condition. PloS One 2014;9:e89447.
30. Depression in adults with a chronic physical health problem (NICE Clinical Guideline 91): Treatment and management. National Institute for Health and Care Excellence, 2009.
31. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care (NICE Clinical Guideline 38). National Institute for Health and Care Excellence, 2006.
32. Tan K, Petrie KJ, Faasse K, Bolland MJ, Grey A. Unhelpful information about adverse drug reactions. BMJ 2014;349:g5019.
33. Amitriptyline BP tablets 10mg. Summary of product characteristics. Datapharm Communications, Actavis UK, March 2011.
34. Uhlig K, Leff B, Kent D, Dy S, Brunnhuber K, Burgers JS, et al. A framework for crafting clinical practice guidelines that are relevant to the care and management of people with multimorbidity. J Gen Intern Med 2014;29:670-9.
35. Boyd C, Kent D. Evidence-based medicine and the hard problem of multimorbidity. J Gen Intern Med 2014;29:552-3.
36. Pronovost PJ. Enhancing physicians' use of clinical guidelines. JAMA 2013;310:2501-2.
37. Ruscitto A, Smith B, Guthrie B. Changes in opioid and other analgesic use 1995-2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain 2014;19:59-66.
38. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20.
39. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37-43.
40. Van Spall H, Toren A, Kiss A, Fowler R. Eligibility criteria of randomized controlled trials published in high-impact general medical journals a systematic sampling review. JAMA 2007;297:8.
41. Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation - determinants of a recommendation's direction and strength. J Clin Epidemiol 2013;66:726-35.
42. Vandvik PO, Brandt L, Alonso-Coello P, Treweek S, Akl EA, Kristiansen A, et al. Creating clinical practice guidelines we can trust, use, and share a new era is imminent. CHEST 2013;144:381-9.